ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

A Range of RRMM Patients Are Eligible for ABECMA®1

Eligible adult patients include those who are1:

Checkmark Icon

Triple-class exposed (patients who have received an IMiD® agent, a PI, and an anti-CD38 monoclonal antibody) and who have received at least 4 prior lines of therapy

Checkmark Icon

Clinically fit (eg, good performance status and adequate organ function)

Eligibility requirements differ for ABECMA and SCT1

The ABECMA pivotal trial included1:

A broad range
of ages

Range: 33-78 years (median 62 years)

Patients who did or did not receive an SCT

92% (n=92) received a prior SCT

LDC prior to
ABECMA infusion

3 days of LDC
(fludarabine [30 mg/m2 IV infusion] and cyclophosphamide [300 mg/m2 IV infusion])

No BCMA testing required1


Patients do not need BCMA testing to receive ABECMA

Planner with Hand Icon

Plan ahead—identify eligible patients early and seek a consultation with a CAR T cell therapy treatment center to evaluate them for ABECMA.

Find a certified treatment center at

BCMA=B-cell maturation antigen; CAR=chimeric antigen receptor; IV=intravenous; LDC=lymphodepleting chemotherapy; PI=proteasome inhibitor; RRMM=relapsed/refractory multiple myeloma; SCT=stem cell transplant.